Acceptability of treatment ‐ leaving the study early · schizophrenia
Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).
1 finding from 1 review
Relapse · schizophrenia
Maintenance treatment with antipsychotic drugs leads to lower relapse: 7 to 12 months compared with placebo/no treatment (high certainty).
1 finding from 1 review
Service use: Number of participants hospitalised · schizophrenia
Maintenance treatment with antipsychotic drugs leads to lower service use: number of participants hospitalised compared with placebo/no treatment (high certainty).
1 finding from 1 review
Death due to suicide · schizophrenia
Maintenance treatment with antipsychotic drugs showed no clear difference in death: due to suicide compared with placebo/no treatment (low certainty).
1 finding from 1 review
QoL · schizophrenia
1 finding from 1 review
Employment · schizophrenia
Maintenance treatment with antipsychotic drugs showed no clear difference in number of participants in employment compared with placebo/no treatment (low certainty).
1 finding from 1 review
Social functioning · schizophrenia
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with OTHER DRUGS (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
1 finding from 1 review
Sexual function: Subjective assessment (number of erections) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Sexual function: Objective assessment (Global efficacy questionnaire, improved erections) · patients with sexual dysfunction due to antipsychotic drug therapy
ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL may leads to higher sexual function: Objective assessment (Global efficacy… compared with PLACEBO (low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review